One coordinated pathway from Kendall Square to the Brazilian patient.
For biotech companies developing therapies for rare and ultra-rare disease, Pharma²⁸ is a single operating partner across regulatory, clinical, data and access.
Small-molecule programs
Novel chemical entities advancing into clinical development.
Advanced therapies
Cell, gene and RNA-based programs requiring specialized infrastructure.
Platform biotechs
Multi-asset companies scaling coordinated global execution.
Repurposing programs
Existing molecules with rare disease evidence potential.
Not only market entry — a clinical development advantage.
For selected rare and ultra-rare programs, Brazil offers deep patient cohorts, high-volume expert centers, experienced investigators and academic research infrastructure aligned with unmet medical need — assets often absent from traditional international market-entry decisions.
- 01
One Coordinated Pathway
Regulatory, clinical, data and access under one operating discipline.
- 02
Disease-Specific Execution
Rare disease is not a portfolio strategy — it is a craft.
- 03
Data-Enabled Intelligence
The platform sits inside execution, not on top of it.
- 04
Long-Term Platform Value
We build cohorts, evidence and access continuity that outlast a single program.
- 01
Program review
Confidential assessment of disease, evidence and geography.
- 02
Feasibility framework
Cohort, site, regulatory and access mapping for Brazil.
- 03
Engagement structure
Aligned incentives, milestones, governance.
- 04
Activation & execution
Sites, investigators, submissions, operations.
- 05
Access & continuity
Reimbursement, distribution, real-world evidence.
A disease-specific playbook
Not a generic CRO handoff.
Institutional access
Direct relationships across Brazilian tertiary medicine.
Data & intelligence assets
Cohort maps, phenotypic signals, RWE.
A Boston operating counterpart
Program cadence familiar to Kendall Square.
Building rare disease infrastructure, together.
If you are advancing a therapy, investing in the space, running a clinical program or coordinating patient identification — start a conversation with us.